Ceruvia Lifesciences Archives

Psychedelics News

Ceruvia Lifesciences

Industry

28 Jun 2022

Ceruvia Receives FDA Approval for Phase 2 OCD Trial

The FDA has given the green light to start a Phase 2 clinical trial to determine the efficacy and safety of Ceruvia’s synthetic psilocybin (SYNP-101) in treating obsessive-compulsive disorder (OCD)....

By Jason Najum

Press Releases

23 Jun 2022

Ceruvia Lifesciences Submits Phase 1 Trial Application With the FDA

Based on a positive pre-IND meeting with the U....

By Microdose NewsDesk

Don’t Miss

30 May 2022

News You Might Have Missed: May 30th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

26 May 2022

Ceruvia Lifesciences Working on Phase 2 Psilocybin Trial for OCD

Ceruvia Lifesciences has submitted an Investigation New Drug (IND) application to begin a Phase 2 clinical trial for the treatment of obsessive-compulsive disorder with psilocybin...

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result